ClinicalTrials.gg
CompletedNCT00836693Updated Jan 4, 2011Results posted

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

A Phase 3 interventional study of tadalafil and placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 21 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
27th of 56
217 · median 199
Started
2009
with 4 others
Phase 3
19 of 57
2 open now
Registered
23rd of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 27th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 19 in phase 3, and was the 23rd registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Erectile Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You are male and aged at least 18 years.
  • Have a history of erectile dysfunction (ED)(defined as the consistent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse) of at least 3 months duration.
  • Agree not to use any other treatment for ED, including herbal and over-the-counter (OTC) medications, during the study
  • You agree to make at least four sexual intercourse attempts with the female sexual study partner during the 4-week run-in period without medication
  • Your entry laboratory test results and medical tests meet study requirements
  • You agree to use the study drug only as instructed by your study doctor and staff and to return any unused study drug and containers at the end of the study or as otherwise instructed by the study doctor.
  • If currently using cholesterol lowering medications (for example: statins) or medications to lower blood pressure (example: angiotensin-converting enzyme (ACE) inhibitors or calcium channel blocker medications), you need to be on a stable dose and you and your study doctor do not expect any dose change during the study.

Exclusion criteria

Exclusion Criteria:

  • You have received previous or current treatment with tadalafil or any other PDE5 inhibitor.
  • Currently receives treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens (except finasteride e.g. Propecia™ or Proscar®, or dutasteride e.g. Avodart®).
  • You have had significant heart disease as determined by your doctor in charge of this study or a member of the doctor's staff.
  • Have a history of significant central nervous system injuries (including stroke or spinal cord injury) within the last 6 months.
  • Have a history of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Drug: tadalafil

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • 5 milligrams (mg) administered orally once a day for 12 weeks

    Also known as: Cialis, LY450190

  • Drugplacebo

    tablet administered orally once a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12

    Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per participant.

    Time frame: Baseline, Week 12

  3. Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night

    NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded.

    Time frame: Baseline, Week 12

  2. Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night

    NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12.

    Time frame: Baseline, Week 12

  3. Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change

    NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12.

    Time frame: Baseline, Week 12

  4. Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary

    The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.

    Time frame: Baseline, 12 weeks

  5. The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint

    The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).

    Time frame: Week 12

  6. Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire

    SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.

    Time frame: Baseline, Week 12

  7. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)

    Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.

    Time frame: Baseline, Week 12

  8. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)

    Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.

    Time frame: Baseline, 12 weeks

  9. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)

    Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

    Time frame: Baseline, Week 12

  10. Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)

    Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

    Time frame: Baseline, 12 weeks

  11. Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of "Yes" Responses

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. "Were you able to achieve at least some erection (some enlargement of the penis)? " Data are presented as the mean percentage of yes responses per participant.

    Time frame: Baseline, 12 weeks

  12. Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of "Yes" Responses

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per participant.

    Time frame: Baseline, 12 weeks

  13. Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of "Yes" Responses

    Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per participant.

    Time frame: Baseline, 12 weeks

  14. Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint

    GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.

    Time frame: Week 12

  15. Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint

    GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.

    Time frame: Week 12

07

Results

Posted Jan 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneTadalafilPlacebo
Started14770
Completed13064
Not completed176
Withdrew: Adverse event41
Withdrew: Sponsor decision01
Withdrew: Physician decision20
Withdrew: Withdrawal by subject94
Withdrew: Protocol violation10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12

Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12
units on a scaleTadalafilPlacebo
Baseline15.5 ± 6.0016.0 ± 6.27
Week 12 Change7.3 ± 6.013.3 ± 5.98
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change. The null hypothesis concerning tadalafil versus placebo was to be rejected if, and only if, the three primary hypotheses (H01, H02, and H03) were all rejected therefore no adjustments for multiple comparisons were made.) · Mean difference (final values): 3.9 · 95% CI 2.2 to 5.5Change = Endpoint - Baseline.
PrimaryChange From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per participant.

Time frame:
Baseline, Week 12
Reported as:
Mean · percentage of yes responses
Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses
percentage of yes responsesTadalafilPlacebo
Baseline60.1 ± 38.7759.9 ± 38.83
Week 12 Change23.2 ± 31.9211.6 ± 25.48
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change. The null hypothesis concerning tadalafil versus placebo was to be rejected if, and only if, the three primary hypotheses (H01, H02, and H03) were all rejected therefore no adjustments for multiple comparisons were made.) · Mean difference (final values): 11.7 · 95% CI 5.1 to 18.3Change = Endpoint - Baseline.
PrimarySexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · percentage of yes responses
Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses
percentage of yes responsesTadalafilPlacebo
Baseline28.2 ± 31.8632.2 ± 35.93
Week 12 Change39.4 ± 34.7119.3 ± 36.18
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change. The null hypothesis concerning tadalafil versus placebo was to be rejected if, and only if, the three primary hypotheses (H01, H02, and H03) were all rejected therefore no adjustments for multiple comparisons were made.) · Mean difference (final values): 18.0 · 95% CI 8.9 to 27.0Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night

NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded.

Time frame:
Baseline, Week 12
Reported as:
Mean · Number of events per night
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night
Number of events per nightTadalafilPlacebo
Baseline (n=122, n=63)2.75 ± 2.2702.44 ± 2.002
Week 12 Change (n=96, n=49)-0.11 ± 2.592-0.09 ± 2.214
SecondaryChange From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night

NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12.

Time frame:
Baseline, Week 12
Reported as:
Mean · minutes
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night
minutesTadalafilPlacebo
Baseline (n=104, n=56)28.487 ± 14.479126.372 ± 11.8969
Week 12 Change (n=65, n=33)-1.553 ± 16.0073-0.398 ± 12.4585
SecondaryChange From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change

NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent of volumetric change
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change
percent of volumetric changeTadalafilPlacebo
Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change-5.96 ± 74.647-50.30 ± 150.321
SecondaryChange From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary

The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · percent
Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary
percentTadalafilPlacebo
Baseline (n=145, n=67)31.0 ± 27.2128.9 ± 25.74
Week 12 Change (n=145, n=66)27.5 ± 25.2911.9 ± 22.00
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12 change. For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 16.2 · 95% CI 9.5 to 22.8Change = Endpoint - Baseline.
SecondaryThe Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint

The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).

Time frame:
Week 12
Reported as:
Mean · units on a scale
The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint
units on a scaleTadalafilPlacebo
The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint72.8 ± 20.6652.7 ± 22.62
Statistical analysis
  • Tadalafil vs Placebo · ANOVA · p = >0.001 (p-value is for Week 12 Change. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 20.0 · 95% CI 13.9 to 26.1
SecondaryChange From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire

SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scaleTadalafilPlacebo
Total (Baseline)47.3 ± 21.9547.9 ± 21.58
Total (Change)20.4 ± 23.858.3 ± 21.14
Sexual Relationship Domain (Baseline)43.0 ± 22.5443.9 ± 21.68
Sexual Relationship Domain (Change)23.4 ± 25.889.7 ± 22.35
Confidence Domain (Baseline)53.1 ± 25.5853.1 ± 24.85
Confidence Domain (Change)16.5 ± 25.586.5 ± 24.57
Self-Esteem Domain (Baseline)50.5 ± 28.1548.5 ± 30.06
Self-Esteem Domain (Change)19.2 ± 27.859.3 ± 30.05
Overall Relationship Domain (Baseline)58.2 ± 31.4762.3 ± 29.01
Overall Relationship Domain (Change)11.0 ± 32.510.9 ± 30.17
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Total (Change). For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 11.7 · 95% CI 5.5 to 18.0Change = Endpoint - Baseline.
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Sexual Relationship Domain(Change).For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 13.2 · 95% CI 6.6 to 19.8Change = Endpoint - Baseline.
  • Tadalafil vs Placebo · ANCOVA · p = 0.0034 (p-value is for Confidence Domain (Change).For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 9.9 · 95% CI 3.3 to 16.5Change = Endpoint - Baseline.
  • Tadalafil vs Placebo · ANCOVA · p = 0.0020 (p-value is for Self-Esteem Domain (Change).For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 11.0 · 95% CI 4.1 to 17.9Change = Endpoint - Baseline.
  • Tadalafil vs Placebo · ANCOVA · p = 0.0653 (p-value is for Overall Relationship Domain(Change).For secondary endpoints, all tests of hypotheses (null hypothesis versus the alternative hypothesis) were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 7.5 · 95% CI -0.5 to 15.6Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)

Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)
units on a scaleTadalafilPlacebo
Baseline6.5 ± 2.997.2 ± 2.81
Week 12 Change2.0 ± 2.780.5 ± 2.02
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change.For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 1.3 · 95% CI 0.7 to 1.9Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)

Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)
units on a scaleTadalafilPlacebo
Baseline6.7 ± 1.816.6 ± 1.87
Week 12 Change0.5 ± 1.93-0.1 ± 1.78
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.0089 (p-value is for Week 12 Change. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 0.7 · 95% CI 0.2 to 1.1Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)

Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)
units on a scaleTadalafilPlacebo
Baseline8.2 ± 2.657.6 ± 2.43
Week 12 Change2.1 ± 2.671.5 ± 2.56
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.0461 (p-value is for Week 12 Change. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 0.8 · 95% CI 0.0 to 1.5Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)

Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)
units on a scaleTadalafilPlacebo
Baseline5.2 ± 2.155.1 ± 2.11
Week 12 Change2.0 ± 2.370.8 ± 2.19
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 1.3 · 95% CI 0.7 to 1.9Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of "Yes" Responses

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. "Were you able to achieve at least some erection (some enlargement of the penis)? " Data are presented as the mean percentage of yes responses per participant.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · percentage of yes responses
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of "Yes" Responses
percentage of yes responsesTadalafilPlacebo
Baseline80.8 ± 28.5274.2 ± 34.26
Week 12 Change12.5 ± 24.039.5 ± 24.67
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = 0.0047 (p-value is for Week 12 Change. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 6.3 · 95% CI 2.0 to 10.7Baseline = Visit 2; Endpoint = the last non-missing post-baseline value until Visit 5; Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of "Yes" Responses

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of yes responses per participant.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · percentage of yes responses
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of "Yes" Responses
percentage of yes responsesTadalafilPlacebo
Baseline11.7 ± 21.1614.6 ± 23.30
Week 12 Change44.1 ± 35.7518.3 ± 32.14
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change.For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 24.5 · 95% CI 14.6 to 34.3Baseline = Visit 2; Endpoint = the last non-missing post-baseline value until Visit 5; Change = Endpoint - Baseline.
SecondaryChange From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of "Yes" Responses

Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of yes responses per participant.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · percentage of yes responses
Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of "Yes" Responses
percentage of yes responsesTadalafilPlacebo
Baseline10.3 ± 20.3612.9 ± 22.11
Week 12 Change43.2 ± 35.5218.5 ± 30.98
Statistical analysis
  • Tadalafil vs Placebo · ANCOVA · p = <0.001 (p-value is for Week 12 Change.For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.) · Mean difference (final values): 23.5 · 95% CI 13.7 to 33.2Baseline = Visit 2; Endpoint = the last non-missing post-baseline value until Visit 5; Change = Endpoint - Baseline.
SecondaryGlobal Assessment Question (GAQ) Question 1 at 12 Week Endpoint

GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.

Time frame:
Week 12
Reported as:
Number · participants
Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint
participantsTadalafilPlacebo
Very Much Better49 ± 33.67 ± 10.1
Much Better41 ± 28.18 ± 11.6
Little Better29 ± 19.919 ± 27.5
No Change14 ± 9.624 ± 34.8
A Little Worse5 ± 3.45 ± 7.2
Much Worse4 ± 1.43 ± 4.3
Very Much Worse2 ± 1.41 ± 1.4
Missing4 ± 2.72 ± 2.9
Statistical analysis
  • Tadalafil vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.0001 (p-value is for Global Assessment Questions GAQ1. For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.)
SecondaryGlobal Assessment Question (GAQ) Question 2 at 12 Week Endpoint

GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.

Time frame:
Week 12
Reported as:
Number · participants
Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint
participantsTadalafilPlacebo
Very Much Better40 ± 27.45 ± 7.2
Much Better49 ± 33.611 ± 15.9
Little Better28 ± 19.217 ± 24.6
No Change17 ± 11.627 ± 39.1
A Little Worse3 ± 2.14 ± 5.8
Much Worse43
Very Much Worse1 ± 0.70 ± 0
Missing4 ± 2.72 ± 2.9
Statistical analysis
  • Tadalafil vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.0001 (p-value is for Global Assessment Question GAQ2.For secondary endpoints, all tests of hypotheses were performed as two-sided tests at the 0.05 significance level (α=0.05) unless otherwise stated.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil—2/147 (1.4%)27/147 (18.4%)
Placebo—1/70 (1.4%)7/70 (10%)
Most frequent serious events
Most frequent serious events
EventTadalafilPlacebo
Ankle fractureInjury, poisoning and procedural complications0/1471/70
Tibia fractureInjury, poisoning and procedural complications0/1471/70
Rib fractureInjury, poisoning and procedural complications1/1470/70
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1470/70
HaemothoraxRespiratory, thoracic and mediastinal disorders1/1470/70
Most frequent other events
Showing 10 of 25
Most frequent other events
EventTadalafilPlacebo
Back painMusculoskeletal and connective tissue disorders5/1471/70
NasopharyngitisInfections and infestations4/1472/70
DyspepsiaGastrointestinal disorders4/1470/70
MyalgiaMusculoskeletal and connective tissue disorders4/1470/70
HeadacheNervous system disorders4/1470/70
InfluenzaInfections and infestations0/1471/70
PharyngitisInfections and infestations0/1471/70
FallInjury, poisoning and procedural complications1/1471/70
Dysthymic disorderPsychiatric disorders0/1471/70
Maxillary antrum operationSurgical and medical procedures0/1471/70

Baseline characteristics

Age Continuous
Age Continuous(years)TadalafilPlaceboTotal
Mean52.2 ± 10.9051.9 ± 10.3552.1 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)TadalafilPlaceboTotal
Female000
Male14770217
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TadalafilPlaceboTotal
White14469213
Asian202
Unknown112
Region of Enrollment
Region of Enrollment(participants)TadalafilPlaceboTotal
Germany391958
Greece19928
Italy271340
Poland311445
Spain311546
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m²))TadalafilPlaceboTotal
Mean27.92 ± 4.68527.74 ± 3.42327.86 ± 4.313
08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Wiessee, D-83707, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13465, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koblenz, D-56068, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 56429, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Catania, 95100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50139, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    L Aquila, 67100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-223, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Legionowo, 05-120, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 91-425, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 00-631, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aravaca, 28023, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Majadahonda, 28222, Spain
09

References and documents

Publications

  • Porst H, Gacci M, Buttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2. PubMed 24119319 ↗
  • Porst H, Brock GB, Kula K, Moncada I, Montorsi F, Basson BR, Kinchen K, Aversa A. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl. 2012 Nov-Dec;33(6):1305-22. doi: 10.2164/jandrol.111.015289. Epub 2012 Jul 12. PubMed 22790642 ↗
  • Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, Sorsaburu S. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naive to PDE5 inhibitors. J Sex Med. 2011 Sep;8(9):2617-24. doi: 10.1111/j.1743-6109.2011.02353.x. Epub 2011 Jun 27. PubMed 21707928 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 4, 2009
Start
Jan 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Jan 4, 2011
Last update
Jan 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00836693
First posted
Feb 4, 2009
Start date
Jan 2009
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Jan 4, 2011
Last update
Jan 4, 2011

Study contacts

Call 1-877-CTLILLY(1-877-285-459) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM eastern time (UTC/GMT -5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion